Takeda: Fabry Disease trials

The registry lists 15 Fabry Disease studies with Takeda as lead sponsor. 2 are open to participants now and 8 have results posted.

Phase 2 3Phase 3 5Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Agalsidase Alfa Enyzme Replacement Therapy in Chinese Children and Adults With Fabry DiseaseRecruitingNCT07187440
• A Study of Replagal in Children and Adults With Fabry Disease in IndiaRecruitingNCT05067868Phase 4
• A Study of REPLAGAL® in Treatment-naive Chinese Participants With Fabry DiseaseCompletedNCT04974749Phase 3Results posted
• A Study of Replagal in Treatment-naïve Adults With Fabry DiseaseTerminatedNCT04840667Phase 3Results posted
• Safety Study of Replagal® Therapy in Children With Fabry DiseaseCompletedNCT01363492Phase 2Results posted
• This Study is Designed to Evaluate PD/PK and Safety of Replagal Manufactured by Two Different Processes.CompletedNCT01304277Phase 2Results posted
• A Multicenter Open-Label Treatment Protocol to Observe the Safety of Replagal (Agalsidase Alfa) Enzyme Replacement Therapy in Canadian Patients With Fabry DiseaseCompletedNCT01298141Phase 3Results posted
• Extension Study of TKT028 Evaluating Safety and Clinical Outcomes of Replagal® in Adult Patients With Fabry DiseaseCompletedNCT01124643Phase 3Results posted
• Safety and Efficacy Study of Several Replagal Dosing Regimens on Cardiac Function in Adults With Fabry DiseaseCompletedNCT00864851Phase 3Results posted
• Replagal Enzyme Replacement Therapy for Children With Fabry DiseaseCompletedNCT00084084Phase 2Results posted
• Early Detection of Fabry DiseaseCompletedNCT05106764
• Fabry Outcome Survey (FOS)CompletedNCT03289065
• Home Therapy With Replagal in Fabry DiseaseCompletedNCT01355146
• Sophisticated Assessment of Disease Burden in Patients With Fabry DiseaseCompletedNCT01210196
• Treatment Protocol of Replagal for Patients With Fabry DiseaseNo longer availableNCT01031173